Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents.
Using data from the ASian Paclitaxel-Eluting Stent Clinical Trial, a 3-center, randomized, placebo-controlled trial of nonpolymeric paclitaxel-coated stents with a single center, 81-patient intravascular ultrasound (IVUS) substudy, the length of a stent that was free of IVUS-detectable intimal hyperplasia measured 3.2 +/- 4.8 mm in placebo stents, 6.1 +/- 5.6 mm in low-dose stents, and 8.7 +/- 6.1 mm in high-dose stents (p = 0.0029). IVUS percent neointima volume obstruction correlated with the length of this IVUS neointima-free segment (r = 0.785, p <0.0001); angiographic late lumen loss and follow-up diameter stenosis also correlated with the IVUS neointima-free length of the stents (r = 0.670, p <0.0001 and r = 0.679, p <0.0001, respectively.
Mintz
Gary S
GS
Department of Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Hong
Myeong-Ki
MK
Raizner
Albert E
AE
Lee
Cheol Whan
CW
Kim
Jae-Joong
JJ
Escolar
Esteban
E
Fearnot
Neal E
NE
Park
Seong-Wook
SW
Park
Seung-Jung
SJ
Weissman
Neil J
NJ
D023903:Coronary Restenosis / Q000000981:diagnostic imaging* / Q000517:prevention & control*; D003331:Coronary Vessels / Q000000981:diagnostic imaging* / Q000473:pathology*; D016503:Drug Delivery Systems; D006801:Humans; D006965:Hyperplasia / Q000000981:diagnostic imaging; D017239:Paclitaxel / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D015607:Stents; D017539:Tunica Intima / Q000000981:diagnostic imaging* / Q000473:pathology*; D018084:Ultrasonography, Interventional
D017239:Paclitaxel